Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
iwMyeloma 2022
25–27 March 2022 | Scottsdale, AZ
VJHemOnc was pleased to be the official media partner for Myeloma 2022, the 15th workshop exploring myeloma biology and innovation. The workshop featured a global expert faculty discussing the latest updates in multiple myeloma. This year’s key topics included the clinical management of myeloma, defining the molecular basis of myeloma in the development of novel targets, immune-based therapies, and measurable residual disease (MRD).
Session 1: Genomics & High-Risk Disease
Defining and Standardizing the Approach to High-Risk Disease
Faith Davies NYU Langone Health, New York City, NY, United States
Aetiologic Translocations and the Pathogenesis of MM
Leif Bergsagel Mayo Clinic, Phoenix, AZ, United States
Whole Genomes, Mutographs and Diversity
Gareth Morgan NYU Langone Health, New York City, NY, United States
Evolutionary Pathways to End-Stage MM
Leo Rasche Würzburg University Hospital , Würzburg, Germany
Genomic Basis of MM Subtypes from the MMRF CoMMpass Studies
Jonathan Keats TGen, Phoenix, AZ, United States
Presentation coming soon.
Lesson from the Sequencing Analysis of the Vk*MYC Mouse Model
Francesco Maura Sylvester Comprehensive Cancer Center, Miami, FL, United States
Using the Vk*MYC Model to Model Progression and Treatment
Marta Chesi Mayo Clinic, Phoenix, AZ, United States
Session 2: Myeloma at the Single-Cell Level
Myeloma at the Single-Cell Level
Irene Ghobrial Dana-Farber Cancer Institute, Boston, MA, United States
Drug Resistance from a Single-Cell Perspective
Yael Cohen Sourasky Medical Center, Tel-Aviv, Israel
Single-Cell Analysis and Drug Resistance
Rodger Tiedemann Princess Margaret Cancer Center, Toronto, Canada
The Microenvironment and Progression
Niels Weinhold Heidelberg University, Heidelberg, Germany
Presentation coming soon.
Predicting Sustained MRD Negativity in Patients Treated with D-KRd
Eileen Boyle University College London, London, NY, United Kingdom
Adipocytes and the Pathogenesis of Myeloma
Noopur Raje Massachusetts General Hospital, Boston, MA, United States
Modulating Remission in the Immune Microenvironment
Ivan Borrello Johns Hopkins University, Baltimore, MD, United States
Session 3: Novel Targets 1
Future of Myeloma Therapy
Jesús San Miguel University of Navarra, Pamplona, Spain
Exploiting Immunogenic Cell Death
Kenneth Anderson Dana-Farber Cancer Institute, Boston, MA, United States
Exploiting IMiD and CELMoD Molecules
Nizar Bahlis Arnie Charbonneau Cancer Institute, Calgary, Canada
Iberdomide in Heavily Refractory Myeloma
Sagar Lonial Emory Winship Cancer Institute, Atlanta, GA, United States
Antibody Treatment for Amyloid
Suzanne Lentzsch Columbia University Medical Center, New York, NY, United States
Personalized Therapy and Basket Trials
Hearn Jay Cho Icahn School of Medicine at Mount Sinai Hospital, New York City, NY, United States
Session 4: MRD-Directed Therapy
MRD-Directed Therapy
Rafael Fonseca Mayo Clinic, Phoenix, AZ, United States
Developing Curative Strategies for Younger Patients
Pieter Sonneveld Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands
Response-Adapted Therapeutic Strategies Based on Flow MRD
Bruno Paiva University of Navarra, Pamplona, Spain
Mass Spec Approaches for MRD
Angela Dispenzieri Mayo Clinic, Rochester, MN, United States
MRD in the Latest MRC Clinical Trials
Charlotte Pawlyn The Institute of Cancer Research, London, United Kingdom
Presentation coming soon.
Session 5: Novel Targets 2
PROTAC Therapy for Difficult to Manipulate Targets
Shaji Kumar Mayo Clinic, Rochester, MN, United States
Modulating Apoptosis with MCL1 and BCL2 Inhibition
Lawrence Boise Emory Winship Cancer Institute, Atlanta, GA, United States
Presentation coming soon.
PIKfyve Inhibitors
Keith Stewart Princess Margaret Cancer Centre, Ontario, Canada
Targeting RAS
Robert Orlowski MD Anderson Cancer Center, Houston, TX, United States
Presentation coming soon.
Emerging Novel Immune Targets
Paola Neri University of Calgary, Alberta, Canada
Session 6: T-Cell Engagers & the Future
T-Cell Engaging Therapy Challenges and Opportunities
Hermann Einsele Würzburg University Hospital, Würzburg, Germany
Idecabtagene Vicleucel Current Status and Future Prospects
Yi Lin Mayo Clinic, Rochester, MN, United States
Bispecifics for Multiple Myeloma
Nina Shah University of California, San Francisco, CA, United States
Ciltacabtagene Autoleucel Current Status and Future Prospects
Thomas Martin University of California, San Francisco, CA, United States
GPRC5D-Directed Bispecifics and CAR-T Therapies
Eric Smith Dana-Farber Cancer Institute, Boston, MA, United States
Targeting FcRH5 as a Strategy in MM
Adam Cohen University of Pennsylvania, Philadelphia, PA, United States
Expert interviews
View all
Meeting Supporters:
Visit the Myeloma Channel for the latest updates from leading experts
